SynapDx Corp., a start up located in Waltham, Mass. and focused on developing and commercializing diagnostic blood-based tests for the early detection of autism, completed a $9m Series A financing.
Investors in the round include Bain Capital Ventures, General Catalyst Partners, and North Bridge Venture Partners.
According to Stanley N. Lapidus, the company’s founder, President and Chief Executive Officer, “The right objective blood-based diagnostic test for autism may help achieve earlier diagnosis, more rapid intervention, and improved outcomes”.
Mr. Lapidus is an experienced life-sciences entrepreneur and inventor with 31 issued patents. He founded and led Cytyc Corp., EXACT Sciences Corp., and Helicos BioSciences Corp.
Co-founders include Jeffrey R. Luber, Esq. and Patrick A. Anquetil, PhD.